Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Elucidating biomarkers of prognosis of 177Lu-PSMA-617-based therapy

Anis Hamid • 6 Jun 2022
ASCO 2022
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617 Antibodies Checkpoint Inhibitors Pembrolizumab
PRINCE

Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, discusses data from the phase I PRINCE trial (NCT03658447), which investigated 177Lu-PSMA-617 plus pembrolizumab for patients with metastatic castration resistant prostate cancer (mCRPC). Circulating tumour cells (CTCs) were found to correlate with patient outcomes, where levels of CTCs declined when patients had favorable outcomes 12 weeks after treatment. PSMA positron emission tomography (PET) metrics such as tumor volume were additionally associated with patient outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Anis Hamid

1:30
How far away are we from implementing CTC-based approaches in prostate cancer?
Anis Hamid • 6 Jun 2022
1:26
Remaining questions on PSMA PET imaging in prostate cancer
Anis Hamid • 6 Jun 2022
1:17
PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer
Anis Hamid • 6 Jun 2022
3:28
CHAARTED: ADT + docetaxel for prostate cancer
Anis Hamid • 13 Feb 2020

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals